Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $216.75 | Prev. Close $222.44 | Circuit Range N/A |
Day Range $216.40 - $222.44 | Year Range $122.80 - $222.44 | Volume 15,635 |
Average Traded $219.64 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Dec-25 | $216.75 | $222.44 | +0.00% |
04-Dec-25 | $216.75 | $222.44 | +3.43% |
02-Dec-25 | $216.30 | $215.06 | -0.01% |
01-Dec-25 | $213.98 | $215.08 | -0.99% |
28-Nov-25 | $216.69 | $217.22 | -0.73% |
26-Nov-25 | $215.91 | $218.81 | +1.01% |
25-Nov-25 | $218.81 | $216.63 | +0.78% |